27-Mar-2024
No headlines found.
Globe Newswire (Wed, 20-Mar 7:30 AM ET)
Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Globe Newswire (Wed, 14-Feb 7:30 AM ET)
Globe Newswire (Tue, 30-Jan 8:00 AM ET)
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement
Globe Newswire (Wed, 24-Jan 8:00 AM ET)
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
Annovis Bio trades on the NYSE stock market under the symbol ANVS.
As of March 27, 2024, ANVS stock price climbed to $12.03 with 165,443 million shares trading.
ANVS has a beta of 0.09, meaning it tends to be less sensitive to market movements. ANVS has a correlation of 0.00 to the broad based SPY ETF.
ANVS has a market cap of $132.47 million. This is considered a Micro Cap stock.
In the last 3 years, ANVS stock traded as high as $132.00 and as low as $5.42.
The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC.
ANVS has underperformed the market in the last year with a return of -36.2%, while the SPY ETF gained +33.6%. In the last 3 month period, ANVS fell short of the market, returning -38.7%, while SPY returned +10.1%. However, in the most recent 2 weeks ANVS has outperformed the stock market by returning +32.3%, while SPY returned +1.7%.
ANVS support price is $11.12 and resistance is $12.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS stock will trade within this expected range on the day.